EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance

Luisa Fernanda Gómez Londoño, Ana Camila Oliveira Souza, Brooks Burt, Sourav Das, Wenbo Ge, Vanessa Meza-Perez iD, Nathan P Wiederhold iD, Anang A Shelat, Christina A Cuomo, Jarrod R Fortwendel, P David Rogers

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag124 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Luisa Fernanda Gómez Londoño und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA. Hauptthemen laut MEDLINE: Aspergillus fumigatus, Antifungal Agents, Triazoles, Drug Resistance, Fungal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, St. Jude Children's Research Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To determine the frequency of cyp51A variants among a contemporary collection of triazole-resistant Aspergillus fumigatus clinical isolates from the USA and compare their specific contribution to reduced triazole susceptibility.

Methods

The genomes of 87 isolates with decreased susceptibility to at least one mould-active triazole antifungal collected between 2007 and 2020 were sequenced. The cyp51A variants were identified and genetically introduced into a cyp51A-null strain. Antifungal susceptibilities for the mould-active triazole antifungals were determined following CLSI guidelines, and variant positions were mapped after protein homology modelling.

Results

Most clinical isolates (60%) carried one of 15 variants that reduced susceptibilities to short-chain (G448S, Y121F, TR46/Y121F/T289A and TR46/Y121F/T289A/N512), long-chain (P216L, F219S and substitutions in the G54 and M220 residues) or multiple (TR34/L98H and TR34/L98H/S297T/F495I) triazoles. While TR34/L98H and TR46/Y121F/T289A were among the most common variants affecting susceptibility, occurring in 13 and 9 isolates, respectively, variants exclusively affecting the coding region and influencing susceptibility were most common, occurring in 31 isolates. A total of 14 isolates (16%) exhibited reduced susceptibility that could not be explained by variants in any known resistance determinants (cyp51A, hmg1 or hapE).

Conclusions

Our findings demonstrate the range of mutations affecting triazole resistance among US isolates and provide a much-needed side-by-side comparison of the impact of these variants on the most currently used mould-active triazole antifungals. Moreover, they underscore the extent to which triazole resistance remains unexplained by known genetic determinants and the need for further discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aspergillus fumigatusAntifungal AgentsTriazolesDrug Resistance, FungalFungal ProteinsCytochrome P-450 Enzyme SystemAspergillosisHumansMicrobial Sensitivity TestsUnited StatesGenetic VariationPrevalence

Substanzen

Antifungal AgentsTriazolesFungal ProteinsCytochrome P-450 Enzyme Systemcytochrome P-450 CYP51A, Aspergillus

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Fungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
  • Department of Molecular Microbiology and Immunology, Brown University, Providence, RI, USA.

ORCID-Profile: Vanessa Meza-Perez, Nathan P Wiederhold

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • St. Jude Children's Research Hospital
  • ALSAC
  • NIH

Zitieren

APA

Gómez Londoño, L. F., Souza, A. C. O., Burt, B., Das, S., Ge, W., Meza-Perez, V., Wiederhold, N. P., Shelat, A. A., Cuomo, C. A., Fortwendel, J. R., & Rogers, P. D. (2026). Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag124

Vancouver

Gómez Londoño LF, Souza ACO, Burt B, Das S, Ge W, Meza-Perez V, et al. Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag124

BibTeX
@article{GmezLondoo2026,
  author = {Gómez Londoño, Luisa Fernanda and Souza, Ana Camila Oliveira and Burt, Brooks and Das, Sourav and Ge, Wenbo and Meza-Perez, Vanessa and Wiederhold, Nathan P and Shelat, Anang A and Cuomo, Christina A and Fortwendel, Jarrod R and Rogers, P David},
  title = {Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag124}
}
Kostenlos starten →